All In Biotech

Drug Trial Radar · NCT04603495

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

430

Actual

Start

Apr 9, 2021

Primary completion

Aug 23, 2023

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Interventions

  • PelabresibDrug

    Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.

  • RuxolitinibDrug

    Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.

  • PlaceboDrug

    Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Splenic Response by Central Radiology Reads at Week 24Time frame: Week 24

Locations

156 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Chandler, Arizona

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Mayo Clinic

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL

    Decatur, Illinois

  • Franciscan Health/Indiana blood and Marrow Transplantation

    Indianapolis, Indiana

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College- New York Presbyterian Hospital

    New York, New York

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Texas Health Science Center - San Antonio

    San Antonio, Texas

  • Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute

    Seattle, Washington

  • USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic

    Buderim, Australia

  • One Clinical Research PTY LTD

    Nedlands, Australia

  • Icon Cancer Centre

    Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peninsula Private Hospital Clinical Trials Unit

    Frankston, Victoria, Australia

  • LKH - Universitätsklinikum Graz; Abteilung für Hämatologie

    Graz, Austria

  • Krankenhaus der Elisabethinen Linz

    Linz, Austria

  • Kepler University Hospital

    Linz, Austria

  • University Hospital Salzburg

    Salzburg, Austria

  • ZNA

    Antwerp, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Hôpital de Jolimont

    La Louvière, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • London Health Sciences Center - Victoria Hospital

    London, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.